维立志博-B(09887)

57.500-2.050-3.44%

社区社区
资讯资讯
资料资料
公告公告

- 最新
- 推荐
公司概况
公司名称
维立志博-B
所属市场
SEHK
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.leadsbiolabs.com
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
南京维立志博生物科技股份有限公司是一家主要从事发现、开发和商业化治疗肿瘤、自身免疫性疾病以及其他严重疾病的新疗法的中国公司。该公司的主要候选药物包括LBL-024、LBL-034、LBL-033、LBL-007等。该公司的LBL-024主要用于治疗肺外神经内分泌癌（EP-NEC）、小细胞肺癌（SCLC）、胆道癌（BTC）及非小细胞肺癌（NSCLC）、食管鳞状细胞癌（ESCC）、肝细胞癌（HCC）、胃癌（GC）及其他实体瘤。该公司还开发了专有技术平台，包括LeadsBody平台（CD3 T-cell engager平台）、X-body平台（4-1BB engager平台）以及其他几个双特异性抗体及融合蛋白平台。该公司主要在国内市场开展业务。
- 04-24
  股份购回
  (1) 2025 年董事会工作报告；(2) 2025 年财务决算报告；(3) 2025 年年报；(4) 2025 年利润分配方案；(5) 建议委任非执行董事；(6) 续聘核数师；(7) 2026 年董事薪酬方案；(8) 发行新股的一般授权；(9) 购回H股的一般授权；(10) 建议修改章程；及年度股东会会议通告
  (1) 2025 年董事会工作报告；(2) 2025 年财务决算报告；(3) 2025 年年报；(4) 2025 年利润分配方案；(5) 建议委任非执行董事；(6) 续聘核数师；(7) 2026 年董事薪酬方案；(8) 发行新股的一般授权；(9) 购回H股的一般授权；(10) 建议修改章程；及年度股东会会议通告
- 04-24
  年度报告
  2025 年度报告
  2025 年度报告
- 03-27
  年度报告
  截至2025年12月31日止年度之年度业绩公告
  截至2025年12月31日止年度之年度业绩公告
- 2025-09-26
  半年度报告
  2025 中期报告
  2025 中期报告
- 2025-08-29
  半年度报告
  截至2025年6月30日止六个月中期业绩公告
  截至2025年6月30日止六个月中期业绩公告
- 2025-07-17
  股份发售
  全球发售
  全球发售

分时
5日
日
周
月

数据加载中...

最高

59.550

今开

59.550

量比

1.51

最低

56.200

昨收

59.550

换手率

0.52%

热议股票

{"pagemeta":{"title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维立志博-B,09887,维立志博-B股票,维立志博-B股票老虎,维立志博-B股票老虎国际,维立志博-B行情,维立志博-B股票行情,维立志博-B股价,维立志博-B股市,维立志博-B股票价格,维立志博-B股票交易,维立志博-B股票购买,维立志博-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"summary","symbol":"09887","data":{"stockData":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":57.5,"timestamp":1780474092008,"preClose":59.55,"halted":0,"volume":800500,"delay":0,"changeRate":-0.034424853064651505,"floatShares":153000000,"shares":199000000,"eps":-1.3985355894477793,"marketStatus":"未开盘","change":-2.05,"latestTime":"06-03 16:08:12","open":59.55,"high":59.55,"low":56.2,"amount":46207917,"amplitude":0.056255,"askPrice":57.5,"askSize":500,"bidPrice":57.2,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-1.3603937097355674,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780536600000},"marketStatusCode":0,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":59.55,"openAndCloseTimeList":[[1780450200000,1780459200000],[1780462800000,1780473600000]],"volumeRatio":1.507029,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"tweetData":null,"newsData":null,"noticeData":{"listData":[{"cdn_pdf":true,"hasAttachments":false,"id":"21102056","market":"hk","labels":[],"media":"港交所","original_id":"N.HK7Rjgpb7uYK","pdf_url":"https://static.tigerbbs.com/c39a1c8278154646a9c05c7fe78932c6","pub_time":1777038300000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"(1) 2025 年董事会工作报告；(2) 2025 年财务决算报告；(3) 2025 年年报；(4) 2025 年利润分配方案；(5) 建议委任非执行董事；(6) 续聘核数师；(7) 2026 年董事薪酬方案；(8) 发行新股的一般授权；(9) 购回H股的一般授权；(10) 建议修改章程；及年度股东会会议通告","symbol":"09887","title":"(1) 2025 年董事会工作报告；(2) 2025 年财务决算报告；(3) 2025 年年报；(4) 2025 年利润分配方案；(5) 建议委任非执行董事；(6) 续聘核数师；(7) 2026 年董事薪酬方案；(8) 发行新股的一般授权；(9) 购回H股的一般授权；(10) 建议修改章程；及年度股东会会议通告","titleType":"股份购回","type":"hkShares","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042403389_c.pdf","us_notice_code":"通函 - [一般性授权 / 回购股份的说明函件 / 在股东批准的情况下重选或委任董事 / 修订宪章文件 / 其他]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"股权股本","type_name_en":"Equity Change","titleTypeEn":"Share Repurchase","event_type":"important_notice","event_name":"股份购回","pubTime":"2026-04-24 21:45","pubTimestamp":1777038300,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"21101880","market":"hk","labels":[],"media":"港交所","original_id":"N.HK5byYUUyaRZ","pdf_url":"https://static.tigerbbs.com/eece1b68b0f342049b7a3071567d85c0","pub_time":1777038240000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2025 年度报告","symbol":"09887","title":"2025 年度报告","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042403305_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [年报]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2026-04-24 21:44","pubTimestamp":1777038240,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20898342","market":"hk","labels":[],"media":"港交所","original_id":"N.HKEVEo7T6t18","pdf_url":"https://static.tigerbbs.com/924c9ef1e0c846ee92059a45cb00d92a","pub_time":1774602000000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2025年12月31日止年度之年度业绩公告","symbol":"09887","title":"截至2025年12月31日止年度之年度业绩公告","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0327/2026032700955_c.pdf","us_notice_code":"公告及通告 - [末期业绩 / 暂停办理过户登记手续或更改暂停办理过户日期]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2026-03-27 17:00","pubTimestamp":1774602000,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20212481","market":"hk","labels":[],"media":"港交所","original_id":"N.HK711fEFihBA","pdf_url":"https://static.tigerbbs.com/1ab0a61717b847a097906eb836129dde","pub_time":1758894540000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2025 中期报告","symbol":"09887","title":"2025 中期报告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0926/2025092602669_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [中期/半年度报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2025-09-26 21:49","pubTimestamp":1758894540,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20108507","market":"hk","labels":[],"media":"港交所","original_id":"N.HK5hHNV65MzN","pdf_url":"https://static.tigerbbs.com/9092eddb3b2d49668ce705c5fab4d8c6","pub_time":1756473540000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2025年6月30日止六个月中期业绩公告","symbol":"09887","title":"截至2025年6月30日止六个月中期业绩公告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0829/2025082903133_c.pdf","us_notice_code":"公告及通告 - [中期业绩]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2025-08-29 21:19","pubTimestamp":1756473540,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19885273","market":"hk","labels":[],"media":"港交所","original_id":"N.HKGRczWturv6","pdf_url":"https://static.tigerbbs.com/3f03895486904a24bf47f5e0b5ef33bc","pub_time":1752704100000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"全球发售","symbol":"09887","title":"全球发售","titleType":"股份发售","type":"hkIPO","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0717/2025071700006_c.pdf","us_notice_code":"上市文件 - [发售以供认购]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"上市文件","type_name_en":"Listing Document","titleTypeEn":"Shares Subscription","event_type":"important_notice","event_name":"股份发售","pubTime":"2025-07-17 06:15","pubTimestamp":1752704100,"notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":true},"companyData":{"profile":{"websiteUrl":"http://www.leadsbiolabs.com","stockEarnings":[{"period":"1week","weight":-0.0866},{"period":"1month","weight":-0.2666},{"period":"3month","weight":0.1133},{"period":"6month","weight":0.1122},{"period":"1year","weight":0.6429},{"period":"ytd","weight":0.1275}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":-0.0177},{"period":"3month","weight":0.0123},{"period":"6month","weight":-0.0173},{"period":"1year","weight":0.0902},{"period":"ytd","weight":0.0001}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"南京维立志博生物科技股份有限公司是一家主要从事发现、开发和商业化治疗肿瘤、自身免疫性疾病以及其他严重疾病的新疗法的中国公司。该公司的主要候选药物包括LBL-024、LBL-034、LBL-033、LBL-007等。该公司的LBL-024主要用于治疗肺外神经内分泌癌（EP-NEC）、小细胞肺癌（SCLC）、胆道癌（BTC）及非小细胞肺癌（NSCLC）、食管鳞状细胞癌（ESCC）、肝细胞癌（HCC）、胃癌（GC）及其他实体瘤。该公司还开发了专有技术平台，包括LeadsBody平台（CD3 T-cell engager平台）、X-body平台（4-1BB engager平台）以及其他几个双特异性抗体及融合蛋白平台。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"维立志博-B","nameEN":"LEADS BIOLABS-B"},"aProfile":null}}}